Verve Therapeutics Inc 2025年季度报告

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, DC 20549 (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934 ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGEACT OF 1934For the transition period from ____________ to ____________Commission File Number: 001-40489 VERVE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Registrant’s telephone number, including area code: (617) 603-0070 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) ofthe Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrantwas required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required tobe submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months(or for such shorter period that the registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-acceleratedfiler, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the ExchangeAct. Large accelerated filer☐Accelerated filer☐Non-accelerated filer☒Smaller reporting company☒Emerging growth company☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extendedtransition period for complying with any new or revised financial accounting standards provided pursuant toSection 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of May 7, 2025, the registrant had 89,143,237 shares of common stock, par value $0.001 per share,outstanding. FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes forward-looking statements that involve substantial risksand uncertainties. All statements, other than statements of historical fact, contained in this QuarterlyReport on Form 10-Q, including statements regarding our strategy, future operations, future financialposition, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,”“expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,”or the negative of these words or other similar expressions are intended to identify forward-lookingstatements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things,statements about: •the timing, progress, design and conduct of our ongoing Heart-2 clinical trial, a Phase 1b clinical trialof VERVE-102, and our ongoing Pulse-1 clinical trial, a Phase 1b clinical trial of VERVE-201, includingstatements regarding the timing of enrollment and the period during which data or updates from suchclinical trials is expected to become available; •the timing of initiation of the planned Phase 2 clinical trial of VERVE-102; •the timing for delivery of the opt-in package to Eli Lilly and Company, or Lilly, and Lilly's decision, andtiming thereof, for the PCSK9 program; •our estimates regarding expenses, future revenue, capital requirements, need for additional financingand the period over which we believe our existing cash, cash equivalents and marketable securities willbe sufficient to fund our operating expenses and capital expenditure requirements; •the timing of and our ability to submit applications for and obtain and maintain regulatory approvals forour current and future product candidates; •the potential therapeutic attributes and advantages of our current and future product candidates; •the timing, progress and conduct of our preclinical studies; •our expectations about the translatability of results from studies in animals into clinical trials inhumans; •our plans to develop and, if approved, subsequently commercialize any product candidates we maydevelop; the rate and degree of market acceptance and clinical utility of our products, if approved; our estimates regarding the addressable patient population and potential market opportunity for ourcurrent and future product candidates; •our commercialization, marketing and manufacturing capabilities and strategy; •our expectations regarding our ability to obtain and maintain intellectual property protection;•our ability to identify additional products, product candidates or technologies with significantcommercial potenti